A Review of Pharmacogenetic Studies Concerning Genetics and Treatment Response in Parkinson’s Disease

Open Access

Issue		BIO Web Conf. Volume 228, 2026 Biospectrum 2025: International Conference on Biotechnology and Biological Science


Article Number		06005
Number of page(s)		10
Section		Medical Biotechnology II
DOI		https://doi.org/10.1051/bioconf/202622806005
Published online		11 March 2026

Su D, Cui Y, He C, Yin P, Bai R, Zhu J, Feng T. Projections for prevalence of Parkinson’s disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021. BMJ. 2025;388:e080474. doi: 10.1136/bmj-2024-080474. [Google Scholar]
Calabresi P, Di Lazzaro G, Marino G, Campanelli F, Ghiglieri V. Advances in understanding the function of alpha-synuclein: implications for Parkinson’s disease. Brain. 2023;146(9):3587–3597. doi: 10.1093/brain/awad167. [Google Scholar]
Subramanian I, Mathur S, Oosterbaan A, Flanagan R, Keener AM, Moro E. Unmet needs of women living with Parkinson's disease: gaps and controversies. Movement Disorders. 2022;37(3):444–455. doi: 10.1002/mds.28894. [Google Scholar]
Iarkov A, Barreto GE, Grizzell JA, Echeverria V. Strategies for the treatment of Parkinson’s disease: beyond dopamine. Frontiers in Aging Neuroscience. 2020;12:4. doi: 10.3389/fnagi.2020.00004. [Google Scholar]
Chaparro-Solano HM, Paz MR, Anis S, Hockings JK, Kundrick A, Piccinin CC, Mata IF. Critical evaluation of the current landscape of pharmacogenomics in Parkinson's disease—what is missing? A systematic review. Parkinsonism & Related Disorders. 2025;130:107206. doi: 10.1016/j.parkreldis.2025.107206. [Google Scholar]
Ma Z, Zou S, Liu R, Li S, Li Z. Socioeconomic development index (SDI) gradients and high BMI-driven pan-cancer burden: a global burden of disease study on mortality, disability, and health inequities (2015–2021). BMC Public Health. 2025;25(1):3295. doi: 10.1186/s12889-025-22663-9. [Google Scholar]
Lipsky RH, Witkin JM, Shafique H, Smith JL, Cerne R, Marini AM. Traumatic brain injury: molecular biomarkers, genetics, secondary consequences, and medical management. Frontiers in Neuroscience. 2024;18:1446076. doi: 10.3389/fnins.2024.1446076. [Google Scholar]
Ramesh S, Arachchige ASPM. Depletion of dopamine in Parkinson's disease and relevant therapeutic options: a review of the literature. AIMS Neuroscience. 2023;10(3):200. [Google Scholar]
Zhao M, Ma J, Li M, Zhang Y, Jiang B, Zhao X, Qin S. Cytochrome P450 enzymes and drug metabolism in humans. International Journal of Molecular Sciences. 2021;22(23):12808. doi: 10.3390/ijms222312808. [Google Scholar]
Pagonabarraga J, Tinazzi M, Caccia C, Jost WH. The role of glutamatergic neurotransmission in the motor and non-motor symptoms in Parkinson's disease: clinical cases and a review of the literature. Journal of Clinical Neuroscience. 2021;90:178–183. doi: 10.1016/j.jocn.2021.05.008. [Google Scholar]
Micaglio E, Locati ET, Monasky MM, Romani F, Heilbron F, Pappone C. Role of pharmacogenetics in adverse drug reactions: an update towards personalized medicine. Frontiers in Pharmacology. 2021;12:651720. doi:10.3389/fphar.2021.651720. [Google Scholar]
Nour M, Senturk U, Polat K. Diagnosis and classification of Parkinson's disease using ensemble learning and 1D-PDCovNN. Computers in Biology and Medicine. 2023;161:107031. doi: 10.1016/j.compbiomed.2023.107031. [Google Scholar]
Qahwaji R, Ashankyty I, Sannan NS, Hazzazi MS, Basabrain AA, Mobashir M. Pharmacogenomics: a genetic approach to drug development and therapy. Pharmaceuticals. 2024;17(7):940. doi: 10.3390/ph17070940. [Google Scholar]
Riederer P, Strobel S, Nagatsu T, Watanabe H, Chen X, Löschmann PA, Monoranu CM. Levodopa treatment: impacts and mechanisms throughout Parkinson’s disease progression. Journal of Neural Transmission. 2025;132(6):743–779. doi: 10.1007/s00702-025-02710-3. [Google Scholar]
Dhiman A, Mehan S, Khan Z, Tiwari A, Das Gupta G, Narula AS. Hereditary patterns and genetic associations in obsessive-compulsive disorder (OCD): neuropsychiatric insights, genetic influences, and treatment perspectives. Current Gene Therapy. 2024. [Google Scholar]
Qahwaji R, Ashankyty I, Sannan NS, Hazzazi MS, Basabrain AA, Mobashir M. Pharmacogenomics: a genetic approach to drug development and therapy. Pharmaceuticals. 2024;17(7):940. doi: 10.3390/ph17070940. [Google Scholar]
Outeiro TF, Alcalay RN, Antonini A, Attems J, Bonifati V, Cardoso F, Ferreira JJ. Defining the riddle in order to solve it: there is more than one “Parkinson's disease”. Movement Disorders. 2023;38(7):1127–1142. doi: 10.1002/mds.29281. [Google Scholar]
Cherian A, Divya KP. Genetics of Parkinson's disease. Acta Neurologica Belgica. 2020;120(6):1307–1315. doi: 10.1007/s13760-020-01379-8. [Google Scholar]
Over L, Brüggemann N, Lohmann K. Therapies for genetic forms of Parkinson’s disease: systematic literature review. Journal of Neuromuscular Diseases. 2021;8(3):341–356. doi: 10.3233/JND-210651. [Google Scholar]
Srinivasan E, Chandrasekhar G, Chandrasekar P, Anbarasu K, Vickram AS, Karunakaran R, Srikumar PS. Alpha-synuclein aggregation in Parkinson's disease. Frontiers in Medicine. 2021;8:736978. doi:10.3389/fmed.2021.736978. [Google Scholar]
Morris HR, Spillantini MG, Sue CM, Williams-Gray CH. The pathogenesis of Parkinson's disease. The Lancet. 2024;403(10423):293–304. doi: 10.1016/S0140-6736(23)01478-2. [Google Scholar]
Radad K, Moldzio R, Krewenka C, Kranner B, Rausch WD. Pathophysiology of non-motor signs in Parkinson’s disease: some recent updating with brief presentation. Exploration of Neuroprotective Therapy. 2023;3(1):24–46. doi: 10.37349/ent.2023.00087. [Google Scholar]
Liu JS, Chen Y, Shi DD, Zhang BR, Pu JL. Pharmacogenomics—a new frontier for individualized treatment of Parkinson’s disease. Current Neuropharmacology. 2023;21(3):536–546. doi: 10.2174/1570159X20666221121143526. [Google Scholar]
Fabbri M, Ferreira JJ, Rascol O. COMT inhibitors in the management of Parkinson’s disease. CNS Drugs. 2022;36(3):261–282. doi: 10.1007/s40263-022-00871-4. [Google Scholar]
Liu JS, Chen Y, Shi DD, Zhang BR, Pu JL. Pharmacogenomics—a new frontier for individualized treatment of Parkinson’s disease. Current Neuropharmacology. 2023;21(3):536–546. doi: 10.2174/1570159X20666221121143526. [Google Scholar]
Magistrelli L, Ferrari M, Furgiuele A, Milner AV, Contaldi E, Comi C, Marino F. Polymorphisms of dopamine receptor genes and Parkinson’s disease: clinical relevance and future perspectives. International Journal of Molecular Sciences. 2021;22(7):3781. doi: 10.3390/ijms22073781. [Google Scholar]
Schneider A, Sari AT, Alhaddad H, Sari Y. Overview of therapeutic drugs and methods for the treatment of Parkinson’s disease. CNS & Neurological Disorders – Drug Targets. 2020;19(3):195–206. doi: 10.2174/1871527319666200127110040. [Google Scholar]
Liu JS, Chen Y, Shi DD, Zhang BR, Pu JL. Pharmacogenomics—a new frontier for individualized treatment of Parkinson’s disease. Current Neuropharmacology. 2023;21(3):536–546. doi: 10.2174/1570159X20666221121143526. [Google Scholar]
Langmia IM, Just KS, Yamoune S, Brockmöller J, Masimirembwa C, Stingl JC. CYP2B6 functional variability in drug metabolism and exposure across populations—implication for drug safety, dosing, and individualized therapy. Frontiers in Genetics. 2021;12:692234. doi: 10.3389/fgene.2021.692234. [Google Scholar]
Leonard H, Blauwendraat C, Krohn L, Faghri F, Iwaki H, Ferguson G, Gan-Or Z. Genetic variability and potential effects on clinical trial outcomes: perspectives in Parkinson’s disease. Journal of Medical Genetics. 2020;57(5):331–338. doi: 10.1136/jmedgenet-2019-106521. [Google Scholar]
Leonard H, Blauwendraat C, Krohn L, Faghri F, Iwaki H, Ferguson G, Gan-Or Z. Genetic variability and potential effects on clinical trial outcomes: perspectives in Parkinson’s disease. Journal of Medical Genetics. 2020;57(5):331–338. doi: 10.1136/jmedgenet-2019-106521. [Google Scholar]
Latif S, Jahangeer M, Razia DM, Ashiq M, Ghaffar A, Akram M, Ansari MA. Dopamine in Parkinson's disease. Clinica Chimica Acta. 2021;522:114–126. doi: 10.1016/j.cca.2021.07.002. [Google Scholar]
Zapała B, Stefura T, Piwowar M, Czekalska S, Zawada M, Hadasik M, Rudzińska-Bar M. The role of single nucleotide polymorphisms of monoamine oxidase B, dopamine D2 receptor, and DOPA decarboxylase receptors among patients treated for Parkinson’s disease. Journal of Molecular Neuroscience. 2022;72(4):812–819. doi: 10.1007/s12031-022-02037-8. [Google Scholar]
Picca A, Guerra F, Calvani R, Romano R, Coelho-Júnior HJ, Bucci C, Marzetti E. Mitochondrial dysfunction, protein misfolding and neuroinflammation in Parkinson’s disease: roads to biomarker discovery. Biomolecules. 2021;11(10):1508. doi: 10.3390/biom11101508. [Google Scholar]
Pirmohamed M. Pharmacogenomics: current status and future perspectives. Nature Reviews Genetics. 2023;24(6):350–362. doi: 10.1038/s41576-023-00579-5. [Google Scholar]
Merghany RM, El-Sawi SA, Naser AFA, Ezzat SM, Moustafa SF, Meselhy MR. A comprehensive review of natural compounds and their structure–activity relationship in Parkinson’s disease: exploring potential mechanisms. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025;398(3):2229–2258. doi: 10.1007/s00210-024-03249-9. [Google Scholar]
Wang RC, Wang Z. Precision medicine: disease subtyping and tailored treatment. Cancers. 2023;15(15):3837. doi: 10.3390/cancers15153837. [Google Scholar]
Tenchov R, Sasso JM, Zhou QA. Evolving landscape of Parkinson’s disease research: challenges and perspectives. ACS Omega. 2025;10(2):1864–1892. doi: 10.1021/acsomega.4c06340. [Google Scholar]
Filip R, Gheorghita Puscaselu R, Anchidin-Norocel L, Dimian M, Savage WK. Global challenges to public health care systems during the COVID-19 pandemic: a review of pandemic measures and problems. Journal of Personalized Medicine. 2022;12(8):1295. doi:10.3390/jpm12081295. [Google Scholar]
Stocchi F, Bravi D, Emmi A, Antonini A. Parkinson disease therapy: current strategies and future research priorities. Nature Reviews Neurology. 2024;20(12):695–707. doi: 10.1038/s41582-024-01089-9. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.